Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Zusammenfassung des Sicherheitsprofils
Die am häufigsten berichteten Nebenwirkungen während der Behandlung sind Schläfrigkeit, Schwindel, Kopfschmerzen, Herzklopfen, Erröten, Bauchschmerzen, Übelkeit, Knöchelschwellung, Ödeme und Müdigkeit.
Tabellarische Liste der Nebenwirkungen
Die folgenden Nebenwirkungen wurden während der Behandlung mit Amlodipin mit folgenden Häufigkeiten beobachtet und berichtet: Sehr häufig (≥1 / 10); gemeinsam (≥1 / 100 bis <1/10); ungewöhnlich (≥1 / 1.000 bis <1/100); selten (≥1 / 10.000 bis <1 / 1.000); sehr selten (<1 / 10.000).
Innerhalb jeder Häufigkeitsgruppe werden Nebenwirkungen in der Reihenfolge der abnehmenden Schwere angegeben:
System organ class |
Frequency |
Adverse reactions |
Blood and lymphatic system disorders |
Very rare |
Leukocytopenia, thrombocytopenia |
Immune system disorders |
Very rare |
Allergic reactions |
Metabolism and nutrition disorders |
Very rare |
Hyperglycaemia |
Psychiatric disorders |
Uncommon |
Depression, mood changes (including anxiety), insomnia |
Rare |
Confusion |
|
Nervous system disorders |
Common |
Somnolence, dizziness, headache (especially at the beginning of the treatment) |
Uncommon |
Tremor, dysgeusia, syncope, hypoaesthesia, paraesthesia |
|
Very rare |
Hypertonia, peripheral neuropathy |
|
Eye disorders |
Common |
Visual disturbance (including diplopia) |
Ear and labyrinth disorders |
Uncommon |
Tinnitus |
Cardiac disorders |
Common |
Palpitations |
Uncommon |
Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation) |
|
Very rare |
Myocardial infarction |
|
Vascular disorders |
Common |
Flushing |
Uncommon |
Hypotension |
|
Very rare |
Vasculitis |
|
Respiratory, thoracic and mediastinal disorders |
Common |
Dyspnoea |
Uncommon |
Cough, rhinitis |
|
Gastrointestinal disorders |
Common |
Abdominal pain, nausea, dyspepsia, altered bowel habits (including diarrhoea and constipation) |
Uncommon |
Vomiting, dry mouth |
|
Very rare |
Pancreatitis, gastritis, gingival hyperplasia |
|
Hepatobiliary disorders |
Very rare |
Hepatitis, jaundice, hepatic enzyme increased* |
Skin and subcutaneous tissue disorders |
Uncommon |
Alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, rash, exanthema, urticaria |
Very rare |
Angioedema, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity |
|
Unknown |
Toxic Epidermal Necrolysis |
|
Musculoskeletal and connective tissue disorders |
Common |
Ankle swelling, muscle cramps |
Uncommon |
Arthralgia, myalgia, back pain |
|
Renal and urinary disorders |
Uncommon |
Micturition disorder, nocturia, increased urinary frequency |
Reproductive system and breast disorders |
Uncommon |
Impotence, gynaecomastia |
General disorders and administration site conditions |
Very common |
Oedema |
Common |
Fatigue, asthenia |
|
Uncommon |
Chest pain, pain, malaise |
|
Investigations |
Uncommon |
Weight increased, weight decreased |
* Meist im Einklang mit Cholestase
Ausnahmefälle des extrapyramidalen Syndroms wurden gemeldet.
Meldung von vermuteten Nebenwirkungen
Die Meldung von vermuteten Nebenwirkungen nach der Zulassung des Arzneimittels ist wichtig. Es ermöglicht eine kontinuierliche Überwachung des Nutzen-Risiko-Verhältnisses des Arzneimittels. Angehörige von Gesundheitsberufen werden gebeten, jeden Verdachtsfall einer Nebenwirkung über das Yellow Card-Programm unter www.mhra.gov.uk/yellowcard zu melden oder im Google Play oder Apple App Store nach MHRA Yellow Card zu suchen.
Produktgruppe : Fertige Medikamente > Herz-Kreislauf- und Urin-Medikamente
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.